Actively Recruiting
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
Led by Second Affiliated Hospital of Wenzhou Medical University · Updated on 2025-07-25
310
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
Sponsors
S
Second Affiliated Hospital of Wenzhou Medical University
Lead Sponsor
T
The Central Hospital of Lishui City
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to conduct analyses the changes of cell growth factors, inflammatory factors, metabolites, plasma proteome, etc. in the blood of patients with ACS (acute coronary syndrome), as well as their correlations with the disease prognosis, based on multi-omics or other related research methods. The main questions it aims to answer are: The growth factors that have significant changes in the peripheral blood of the ACS population, especially fibroblast growth factors? Inflammatory factors and chemokines related to the onset of ACS? The metabolites and proteins that are significantly altered in the peripheral blood after the onset of ACS? Researchers will compare ACS population to CCS (Chronic Coronary Syndrome) population, and control group (patients without coronary artery stenosis, valvular heart disease, structural heart disease, or any other kind of cardiomyopathy).The peripheral venous blood from the participants will be collected within 24 hours after their admission to the hospital.
CONDITIONS
Official Title
A Study on the Peripheral Blood in Patients With Acute Coronary Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For ACS group STEMI: cTn >99th ULN or CK-MB >99th ULN
- ST-segment elevation with a convex upward shape
- Plus one or more of persistent chest pain, abnormal heart wall motion on echocardiogram, or abnormal coronary angiography
- For NSTEMI: cTn >99th ULN or CK-MB >99th ULN
- Plus one or more of persistent chest pain, new ST-segment depression or inverted T waves, abnormal heart wall motion, or abnormal coronary angiography
- For UA: normal cTn
- Ischemic chest pain with transient ST-segment depression or inverted T waves on ECG
- Evidence of coronary artery stenosis (≥50% narrowing)
- For CCS group: clinical diagnosis consistent with CCS categories including stable angina, ischemic cardiomyopathy, post-ACS stable phase, long-term CAD management, vasospastic or microvascular disease, or asymptomatic CAD
- Normal or stable cTn and no ACS changes on ECG
- ≥50% narrowing in at least one major coronary artery
- For control group: no coronary artery stenosis, valvular heart disease, structural heart disease, or other cardiomyopathies
You will not qualify if you...
- Women who are pregnant or breastfeeding
- Patients with cancer or malignant tumors
- Severe liver or kidney dysfunction
- Severe blood disorders
- Autoimmune diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lishui Central Hospital
Lishui, Zhejiang, China
Actively Recruiting
Research Team
C
Chao Niu, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here